Bonus BioGroup Ltd. Logo

Bonus BioGroup Ltd.

A clinical-stage biotech firm developing cell therapy and tissue engineering products.

BONS | TA

Overview

Corporate Details

ISIN(s):
IL0004850116
LEI:
Country:
Israel
Address:
Park P.O.B 15143, 31905 Haifa

Description

Bonus BioGroup Ltd. is a clinical-stage biotechnology company that develops cell therapy and tissue engineering products. The company's research focuses on addressing unmet medical needs related to tissue damage, inflammation, and immune response. Its core technology platforms include an investigational cell therapy designed to modulate inflammation and promote tissue repair using mesenchymal cells, and a viable tissue engineering approach that combines patient-derived cells with biomaterials for bone regeneration. Key product candidates in its pipeline are BonoFill, a personalized, tissue-engineered bone graft for orthopedic and maxillofacial defects, and MesenCure, an allogeneic cell therapy developed to target inflammation and tissue damage. These investigational therapies are currently being evaluated in clinical trials for safety and efficacy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-27 11:48
Company Presentation- 2025
Hebrew (modern) 9.0 MB
2025-05-27 11:48
Company Presentation- 2025
Russian 43.6 KB
2023-07-11 12:06
Company Presentation, July 2023
English 3.4 MB
2023-07-11 12:06
Company Presentation, July 2023
Russian 44.7 KB
2022-04-11 16:02
Company Presentation
English 8.2 MB
2022-04-11 16:02
Company Presentation
Russian 47.1 KB
2022-04-11 15:01
Company Presentation
Hebrew (modern) 11.0 MB
2022-04-11 15:01
Company Presentation
Russian 47.1 KB
2022-01-10 10:52
The company inteds to publish an immediate report, trading will be open after …
Hebrew (modern) 105.1 KB

Automate Your Workflow. Get a real-time feed of all Bonus BioGroup Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bonus BioGroup Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bonus BioGroup Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Certara, Inc. Logo
Accelerates drug development using biosimulation software, technology, and services.
United States of America
CERT
CervoMed Inc. Logo
A clinical-stage biotech developing treatments for age-related neurologic disorders.
United States of America
CRVO
Chabiotech Co.,Ltd. Logo
Develops cell/gene therapies and provides CDMO and bio-banking services.
South Korea
085660
CHAMPIONS ONCOLOGY, INC. Logo
A CRO providing end-to-end solutions to accelerate oncology drug development.
United States of America
CSBR
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Logo
A contract research organization supporting drug discovery and development.
United States of America
CRL
Chiome Bioscience Inc. Logo
Clinical-stage biotech company developing antibody-based therapeutics.
Japan
4583
Chordate Medical Holding AB Logo
Develops a patented, drug-free neuromodulation treatment for migraine and rhinitis.
Sweden
CMH
Chordia Therapeutics,Inc Logo
Clinical-stage biotech developing novel cancer therapies targeting RNA deregulation.
Japan
190A
Cibus, Inc. Logo
Develops and licenses plant traits using non-GMO precision gene-editing technology.
United States of America
CBUS
Circio Holding ASA Logo
Clinical-stage company developing circular RNA medicines and immunotherapies.
Norway
CRNA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.